EP2006286A4 - ISOXAZOLE DERIVATIVE AND ISOTHIAZONE DERIVATIVITY WITH ANTICIPATING EFFECT ON 11 TYPE I BETA HYDROXYSTEROIDDEHYDROGENASE - Google Patents

ISOXAZOLE DERIVATIVE AND ISOTHIAZONE DERIVATIVITY WITH ANTICIPATING EFFECT ON 11 TYPE I BETA HYDROXYSTEROIDDEHYDROGENASE

Info

Publication number
EP2006286A4
EP2006286A4 EP07739976A EP07739976A EP2006286A4 EP 2006286 A4 EP2006286 A4 EP 2006286A4 EP 07739976 A EP07739976 A EP 07739976A EP 07739976 A EP07739976 A EP 07739976A EP 2006286 A4 EP2006286 A4 EP 2006286A4
Authority
EP
European Patent Office
Prior art keywords
derivative
beta
inhibitory activity
hydroxysteroid dehydrogenase
dehydrogenase type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07739976A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2006286A9 (en
EP2006286A2 (en
Inventor
Tomoyuki Ogawa
Nobuo Chomei
Koji Masuda
Satoru Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of EP2006286A2 publication Critical patent/EP2006286A2/en
Publication of EP2006286A9 publication Critical patent/EP2006286A9/en
Publication of EP2006286A4 publication Critical patent/EP2006286A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EP07739976A 2006-03-30 2007-03-28 ISOXAZOLE DERIVATIVE AND ISOTHIAZONE DERIVATIVITY WITH ANTICIPATING EFFECT ON 11 TYPE I BETA HYDROXYSTEROIDDEHYDROGENASE Withdrawn EP2006286A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006094057 2006-03-30
JP2006280893 2006-10-16
PCT/JP2007/056538 WO2007114124A1 (ja) 2006-03-30 2007-03-28 Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有するイソキサゾール誘導体およびイソチアゾール誘導体

Publications (3)

Publication Number Publication Date
EP2006286A2 EP2006286A2 (en) 2008-12-24
EP2006286A9 EP2006286A9 (en) 2009-07-22
EP2006286A4 true EP2006286A4 (en) 2010-04-07

Family

ID=38563393

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07739976A Withdrawn EP2006286A4 (en) 2006-03-30 2007-03-28 ISOXAZOLE DERIVATIVE AND ISOTHIAZONE DERIVATIVITY WITH ANTICIPATING EFFECT ON 11 TYPE I BETA HYDROXYSTEROIDDEHYDROGENASE

Country Status (5)

Country Link
US (1) US8017638B2 (ja)
EP (1) EP2006286A4 (ja)
JP (1) JP5240775B2 (ja)
TW (1) TW200806640A (ja)
WO (1) WO2007114124A1 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101312951A (zh) 2005-11-21 2008-11-26 盐野义制药株式会社 具有Ⅰ型11β羟基类固醇脱氢酶抑制活性的杂环化合物
EP2088136A4 (en) 2006-11-02 2012-10-10 Shionogi & Co PROCESS FOR PRODUCING HYDROXYADAMANTANE-AMINE
US7998992B2 (en) 2007-03-30 2011-08-16 Institute Of Medicinal Molecular Design, Inc. Oxazolidinone derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1
PL2163543T3 (pl) * 2007-05-18 2015-06-30 Shionogi & Co Heterocykliczna pochodna zawierająca azot o aktywności hamującej dehydrogenazę 11-beta-hydroksysteroidową typu I
EP2221380A1 (en) 2007-09-27 2010-08-25 Shionogi & Co., Ltd. Method for producing hydroxylated adamantane using cytochrome p450
US20100022590A1 (en) * 2008-01-17 2010-01-28 Biovitrum Ab (Publ.) Novel compounds
EP2243479A3 (en) 2009-04-20 2011-01-19 Abbott Laboratories Novel amide and amidine derivates and uses thereof
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
CN103649066B (zh) * 2011-06-10 2016-08-17 爱思开生物制药株式会社 5-氨甲酰基-金刚烷-2-基酰胺衍生物、其药学上可接受的盐及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE53068B1 (en) * 1981-06-15 1988-05-25 Merck & Co Inc Diamino isothiazole-1-oxides and -1,1-dioxides as gastic secretion inhibitors
JPS59128326A (ja) 1983-01-13 1984-07-24 Shionogi & Co Ltd 抗真菌剤
JPS59128306A (ja) 1983-01-13 1984-07-24 Shionogi & Co Ltd 農業用殺菌剤
US4562187A (en) * 1985-01-22 1985-12-31 Hoechst-Roussel Pharmaceuticals Inc. (Isoxazol-3-yl)arylmethanones, compositions and pharmaceutical use
US5001124A (en) 1990-02-02 1991-03-19 Syntex (U.S.A.) Inc. 4-isoxazolecarboxamide derivatives
JP2002069061A (ja) 2000-08-30 2002-03-08 Canon Inc オキサゾール化合物及びそれを用いた有機発光素子
EP1275301A1 (en) 2001-07-10 2003-01-15 Bayer CropScience S.A. Trisubstituted heterocyclic compounds and their use as fungicides
CZ2004168A3 (cs) 2001-08-06 2004-05-12 Pharmaciaáitaliaás@P@A Aminoizoxazolové derivátyŹ účinné jako kinázové inhibitoryŹ způsob jejich přípravy a farmaceutické prostředkyŹ které je obsahují
JP3456702B1 (ja) * 2001-11-21 2003-10-14 三共アグロ株式会社 Ｎ−ヘテロアリールニコチンアミド誘導体及びその製造方法
DE60233751D1 (de) 2001-11-21 2009-10-29 Mitsui Chemicals Agro Inc N-heteroarylnikotinamidderivate
PL370111A1 (en) 2001-11-22 2005-05-16 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
GB0230087D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
ATE482747T1 (de) * 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc Neue amide derivate und deren pharmazeutische verwendungen
EP1653949A4 (en) * 2003-08-07 2009-04-22 Merck & Co Inc PYRAZOL CARBOXAMIDE AS AN INHIBITOR OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1
JP2007261945A (ja) 2004-04-07 2007-10-11 Taisho Pharmaceut Co Ltd チアゾール誘導体
US20050245533A1 (en) * 2004-04-29 2005-11-03 Hoff Ethan D Inhibitors of the 11-beta-hydroxysteroid dehydrogenaseType 1 enzyme and their therapeutic application
US20050261302A1 (en) * 2004-04-29 2005-11-24 Hoff Ethan D Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application
US20050245532A1 (en) * 2004-04-29 2005-11-03 Hoff Ethan D Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application
US20050245534A1 (en) 2004-04-29 2005-11-03 Link James T Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
WO2005108359A1 (en) 2004-05-06 2005-11-17 Pfizer Inc. Novel compounds of proline and morpholine derivatives
CN1980889B (zh) 2004-05-07 2010-11-10 詹森药业有限公司 11-β羟基类固醇脱氢酶抑制剂的金刚烷基吡咯烷-2-酮衍生物
DE502004007806D1 (de) 2004-06-23 2008-09-18 I & T Innovation Tech Entw Manteln mehrerer kabelleiter
WO2006002361A2 (en) 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
WO2006012227A2 (en) 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
EA012263B1 (ru) 2004-08-30 2009-08-28 Янссен Фармацевтика Н.В. Производные n-2-адамантанил-2-феноксиацетамида в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
CN101039908B (zh) 2004-08-30 2010-06-23 詹森药业有限公司 作为11-β羟甾类脱氢酶抑制剂的三环内酰胺衍生物
EP1812407A2 (en) 2004-11-02 2007-08-01 Pfizer, Inc. Novel compounds of substituted and unsubstituted adamantyl amides
WO2006074330A2 (en) 2005-01-05 2006-07-13 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
ES2386365T3 (es) 2005-01-05 2012-08-17 Abbott Laboratories Derivados de adamantilo como inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa de tipo 1
US20060148871A1 (en) * 2005-01-05 2006-07-06 Rohde Jeffrey J Metabolic stabilization of substituted adamantane
GB0506133D0 (en) 2005-03-24 2005-05-04 Sterix Ltd Compound
US8952176B2 (en) 2005-06-07 2015-02-10 Shionogi & Co., Ltd. Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity
CN101312951A (zh) 2005-11-21 2008-11-26 盐野义制药株式会社 具有Ⅰ型11β羟基类固醇脱氢酶抑制活性的杂环化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO2007114124A1 *

Also Published As

Publication number Publication date
US20090131491A1 (en) 2009-05-21
EP2006286A9 (en) 2009-07-22
TW200806640A (en) 2008-02-01
US8017638B2 (en) 2011-09-13
WO2007114124A1 (ja) 2007-10-11
JPWO2007114124A1 (ja) 2009-08-13
JP5240775B2 (ja) 2013-07-17
EP2006286A2 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
EP2006286A4 (en) ISOXAZOLE DERIVATIVE AND ISOTHIAZONE DERIVATIVITY WITH ANTICIPATING EFFECT ON 11 TYPE I BETA HYDROXYSTEROIDDEHYDROGENASE
EP2163543A4 (en) NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE WITH 11BETA HYDROXYSTEROID DEHYDROGENASE TYPE-1 INHIBITORY ACTIVITY
EP2141154A4 (en) OXAZOLIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11-HYDROXYSTEOID DEHYDROGENASE TYPE I
EP1953145A4 (en) HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY OF 11-HYDROXYSTEROID DEHYDROGENASE TYPE I
AP2812A (en) Modified dicamba monooxygenase enzyme and methods of its use
IL196989A0 (en) Cyclic ii-?? hydroxysteroid dehydrogenase type 1 inhibitors
EP1948812A4 (en) ENZYM AND METHODS FOR TREATING A BIOMASS
EP2072277A4 (en) WRITING DEVICE AND WRITING SET
EP1894919A4 (en) HETEROCYCLIC COMPOUND HAVING TYPE I 11 -BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITION ACTIVITY
EP2083074A4 (en) MODIFIED FLAVIN-ADENINE-DINUCLEOTIDE-DEPENDENT GLUCOSE-DEHYDROGENASE
IL182904A0 (en) Transseptal catheterization assembly and methods
ZA200810074B (en) Cleaning and/or treatment compositions comprising mutant alpha-amylases
IL193530A0 (en) Benzothiazol derivatives as beta2 adrenoreceptor agonists
ZA200810703B (en) Compounds having a potentiating effect on the activity of ethionamide and uses thereof
EP2083070A4 (en) MICROORGANISM WITH ABILITY TO COMBAT PLANT DISEASES AND PLANT DISEASES USING THE MICROORGANISM OF COMBATING AGING
HK1224181A1 (zh) 抑制 氧化酶活性的組合物
EP2062887A4 (en) NOVEL AMINOPYRIDINE DERIVATIVE HAVING SELECTIVE AURORA A INHIBITION ACTIVITY
EP2208728A4 (en) HETEROCYCLIC DERIVATIVE DERIVATIVE DERIVATIVE TO 11 -? - HYDROXYSTEROIDDEHYDROGENASE TYPE I
EP1996009A4 (en) METHODS AND COMPOSITIONS FOR ENHANCING ENZYMA ACTIVITY IN TRANSGENIC PLANTS
EP2257177A4 (en) NEW EXTRACTS OF DESCHAMPSIA ANTARCTICA DESV. WITH ANTINEOPLASTIC EFFECT
EP1969372A4 (en) METHOD AND COMPOSITIONS FOR DETECTING ENZYMATIC ACTIVITY
EP2357229A4 (en) HYDROXYLASE GENE AND USE THEREOF
EP2017279A4 (en) NEW AMINO-PYRIDINE DERIVATIVE WITH AURORA A SELECTIVE HEMORATIVE EFFECT
EP1841747A4 (en) DERIVATIVES OF OXAZOLE HYDROXAMIC ACID AND ITS USE
GB0702414D0 (en) Oxazole and thiazole derivatives and their uses 2

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAB Information related to the publication of an a document modified or deleted

Free format text: ORIGINAL CODE: 0009199EPPU

17P Request for examination filed

Effective date: 20081015

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20100309

17Q First examination report despatched

Effective date: 20110207

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120731